Gamma Vaccines has signed a deed of assignment with the University of Adelaide for the rights to commercialise vaccines for NDV (Newcastle disease), either alone or in combination with our other proprietary vaccines.
05/10/2024
News
- 12/09/2024
Gamma vaccines signs international collaboration agreement.
Gamma vaccines has entered a collaboration agreement with Capricorn Technologies GmBH (Austria) and Aptum Adjuvants Ltd (UK) to investigate and develop vaccines that marry Gamma Vaccines manufacturing technology with Capricorn’s novel vaccines and Aptum’s innovative approach to increasing vaccine effectiveness.
- 05/09/2024
Gamma Vaccines files patent on combination vaccines
Gamma Vaccines has filed a patent application on combination vaccines that incorporate our photon-inactivated vaccine with other immunogens, to produce combination vaccines which are more effective that current vaccines alone.
- 27/05/2024
Gamma Vaccines receives R&D tax credit.
Gamma vaccines receives an R&D Tax Credit for R&D conducted in FY2023 for the amount of $28,538.84.
- 19/12/2023
Gamma Vaccines signs licence agreement with Griffith University to commercialise Chikungunya vaccine.
Gamma Vaccines has been granted a worldwide exclusive licence to commercialize a patented Chikungunya vaccine from Griffith University, OLD, which includes the rights to sublicence this technology.